We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SIF Banat-Crisana reached a share of 10 per cent in the capital of the pharmaceutical company Biofarm, following several transactions carried on through the Bucharest Stock Exchange (BVB).
Bothell, Wash.-based Nastech Pharmaceutical has entered into an agreement with Procter & Gamble Pharmaceuticals (P&G) to manufacture and supply the investigational PTH1-34 nasal spray for the treatment of osteoporosis, the companies have reported.
Swiss drugmaker Novartis and Human Genome Sciences (HGS), based in Maryland, have entered into an agreement to develop and commercialize Albuferon (albumin-interferon alpha 2b) for chronic hepatitis C and all other uses.
Australian drugmaker EvoGenix has entered into a technology collaboration agreement with CSL Limited, also based in Australia, to develop human antibody therapeutics.
Leading pharmaceutical manufacturer Wockhardt Monday signed an in-licensing agreement with a British company specialising in dermatology to market a patented product for the treatment of a pigmentation disorder.
German biopharma firm Sandoz has won a landmark first-of its-kind biosimilar drug approval in the US after a long battle with the Food and Drug Administration (FDA).
Glenmark Pharmaceuticals Inc (GPI), a wholly owned US subsidiary of Glenmark Pharmaceuticals, has announced a royalty deal with Paul Capital Partners Royalty fund, an international healthcare investment fund to develop generic prodcuts in the dermatology portfolio for the billion dollar US markets.
A Beijing court has upheld drug giant Pfizer's patent for Viagra, ruling against the country's patent review board in a case considered pivotal for countering piracy of pharmaceuticals. An official at the Beijing No. 1 Intermediate People's Court on Monday confirmed the decision but said she could not provide other information.